FDA Approves KEYTRUDA® and KEYTRUDA QLEX , Each With Padcev® , as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer

Source Summary

First and only PD-1 inhibitor plus antibody-drug conjugate regimens approved for patients with MIBC regardless of cisplatin eligibility Approvals based on Phase 3 KEYNOTE-B15 trial, combined with previous approvals based on Phase 3 KEYNOTE-905 trial, bring forward new options for these patien...